Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

<p>Abstract</p> <p>Background</p> <p>Thalassaemia major (TM) patients need regular blood transfusions that lead to accumulation of iron and death from heart failure. Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improve...

Full description

Bibliographic Details
Main Authors:	Gotsis Efstathios D, Aessopos Athanassios, Piga Antonio, Ladis Vasili, Karagiorga Markissia, Berdoukas Vasili, Alam Mohammed H, Carpenter John, Alpendurada Francisco, Smith Gillian C, Tanner Mark A, Westwood Mark A, Galanello Renzo, Roughton Michael, Pennell Dudley J
Format:	Article
Language:	English
Published:	BMC 2011-07-01
Series:	Journal of Cardiovascular Magnetic Resonance
Online Access:	http://www.jcmr-online.com/content/13/1/34

Similar Items

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
by: Alpendurada Francisco, et al.
Published: (2012-01-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance (CMR) imaging in transfusion dependent thalassemia major (TM)
by: Gotsis Efstathios, et al.
Published: (2007-07-01)

Treating thalassemia major-related iron overload: the role of deferiprone
by: Berdoukas V, et al.
Published: (2012-10-01)

Protective action of deferiprone and deferoxamine in erythrocytes isolated from patients with β-thalassemias
by: Alisson F. Santos, et al.
Published: (2009-01-01)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)

Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial
by: Sasan Hejazi, et al.
Published: (2016-06-01)

Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent
by: Rosalina Josep, et al.
Published: (2012-10-01)

Analysis deferoxamine, deferiprone, and deferasirox in β-thalassemia patients’ plasma by capillary electrophoresis and copper nanoclusters
by: Hung-Ju Lin, et al.
Published: (2017)

Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01)

Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
by: Taher AT, et al.
Published: (2016-12-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016-01-01)

CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT
by: Athanasios Aessopos, et al.
Published: (2009-07-01)

Cardiac failure in β-thalassemia: diagnosis, prevention and management
by: A. Aessopos, et al.
Published: (2011-12-01)

Side effect of deferiprone as iron chelator in patient with thalassemia
by: Mikhael Yosia, et al.
Published: (2018-01-01)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
by: Gyan Chand, et al.
Published: (2009-04-01)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

Efficacy of defroxamine- deferiprone on cardiac function of patients with major thalassemia
by: Mirbehbahani NB, et al.
Published: (2015-09-01)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
by: Ricchi Paolo, et al.
Published: (2011-02-01)

Cataract Formation due to use of Deferiprone in a Patient with Thalassemia Major
by: Barbaros sahin Karagun, et al.
Published: (2015-03-01)

Protective action of deferiprone and deferoxamine in erythrocytes isolated from patients with β-thalassemias Ação protetora de deferiprona e desferoxamina nos eritrócitos isolados de pacientes com β-talassemias
by: Alisson F. Santos, et al.
Published: (2009-01-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Improving adherence with deferoxamine regimen in thalassemia major using education
by: Gholamreza Pouladfar, et al.
Published: (2006-02-01)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
by: Pibiri Martina, et al.
Published: (2008-02-01)

Prevention of Cardiomyopathy in Transfusion-Dependent Homozygous Thalassaemia Today and the Role of Cardiac Magnetic Resonance Imaging
by: Athanassios Aessopos, et al.
Published: (2009-01-01)

Pharmacokinetic study of deferiprone and deferasirox with different treatment regimens in Taiwanese thalassemia patients
by: Ta-Shu Song, et al.
Published: (2014)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)

Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia
by: F. Rashidi ghader, M.D, et al.
Published: (2007-01-01)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
by: Capra Marcello, et al.
Published: (2011-02-01)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
by: Hayder M Al-Kuraishy, et al.
Published: (2017-01-01)

Beta-thalassemia
by: Origa Raffaella, et al.
Published: (2010-05-01)

Rapid Iron Loading in Heart and Liver in a Patient with Transfusion Dependent Thalassaemia after Brief Poor Compliance with Iron Chelation Therapy
by: Shahina Daar, et al.
Published: (2010-12-01)

WHAT A HİGH FREQUENCY OF DEFERİPRONE-İNDUCED AGRANULOCYTOSİS İN A TURKİSH POPULATİON OF THALASSEMİA MAJOR
by: Mehmet Helvacı, et al.
Published: (2015-03-01)

Biventricular dimensions and function in pediatric sickle-cell disease and thalassemia major patients without cardiac iron
by: Meloni Antonella, et al.
Published: (2013-01-01)

Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance
by: Tanner Mark A, et al.
Published: (2011-01-01)

Urinary iron excretion induced by intravenous infusion of deferoxamine in ß-thalassemia homozygous patients
by: Boturão-Neto E., et al.
Published: (2002-01-01)

Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major
by: Westwood Mark A, et al.
Published: (2009-01-01)

Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
by: Rasul Jameel Ali, et al.
Published: (2020-12-01)